Sagent Recalls Four Lots of Levetiracetam
The antiseizure medication affected by the recall could have sterility issues.
Sagent Pharmaceuticals is recalling four lots of Levetiracetam Injection, which is used for the treatment of certain types of seizures. It is packaged in a 5 mL single-does vial and was distributed from March 2021 until November 2021.
The recall is because of a lack of container closure integrity, which could lead to sterility issues. To date, Sagent has not received reports of any product complaints or adverse events associated with this issue.
The NDC number of the affected product is 25021-780-05. The lot numbers included in the recall include:
- B0G85VB, with an expiration date of June 2022
- B0K88VA, with an expiration date of September 2022
- B0K89VA, with an expiration date of September 2022
- B1G194A, with an expiration date of June 2023
Levetiracetam label
FDA Accepts NDA for Zoliflodacin, Potentially First Gonorrhea Antibiotic in Decades
June 13th 2025The FDA has accepted a New Drug Application for zoliflodacin, a first-in-class oral antibiotic for treating uncomplicated gonorrhea, offering a potential new option amid rising antibiotic resistance.
Read More
